REG - Ergomed plc - Ergomed 2018 Trading Update

ErgomedAnnouncement

31/01/2019 07:05

RNS Number : 6074O
Ergomed plc
31 January 2019
 


PRESS RELEASE
   FOR IMMEDIATE RELEASE
 
 
 
Ergomed 2018 Trading Update
 
Revenues and EBITDA in line with market expectations
 
Significant turnaround in profitability in second half, coupled with strong sales of new business and contracted backlog, positions Ergomed well for 2019
 
 
 
Guildford, UK - 31 January 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, today provides a trading update for the year ended 31 December 2018.
 
Net Service Fee revenues for 2018 are expected to be approximately £46.5 million (2017: £39.6 million), in line with current market expectations, prior to any impact of IFRS 15. Growth in both pharmacovigilance (PV) and CRO is anticipated to be broadly in line with expectations, with the PV business continuing to perform strongly and show growth of more than 20%.
 
In terms of profitability, the second half of the year has seen strong operational performance and, with the cost reduction programme implemented by management having an impact, adjusted EBITDA is also expected to be in line with market expectations.
 
Driven by sales of new business of £76 million in 2018 (2017: £54 million), Ergomed's order book remains robust and it is expected that the backlog at the end of 2018 will be approximately £106 million (2017: £88 million, both including reimbursement revenues), prior to any IFRS 15 adoption adjustments.
 
IFRS 15 (revenue recognition) will be adopted with effect from 1 January 2018. At the time of presenting the Preliminary Results a clear reconciliation of the non-cash accounting adjustments associated with revenue and backlog impacts will be provided.
 
Dr Miroslav Reljanovic, Executive Chairman of Ergomed, said: "We have worked hard to deliver significantly improved results in the second half in 2018. Based on our contracted backlog and re-aligned cost base, I am optimistic we can deliver our 2019 growth targets. We continue to execute on our strategy of focusing on services, specifically on the opportunities in pharmacovigilance and orphan drug development."
 
 
 
- Ends -
 
Enquiries:
 




Ergomed plc


   Tel: +44 (0) 1483 503205




Dr Miroslav Reljanovic (Executive Chairman)


 




Stuart Jackson (Chief Financial Officer)


 




 


 




Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)


 




James Black (Broker)


 




 


 




 


 




Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


 




 


 




MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke


 




 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTWGUGPGUPBPPU